VB-111, is a first-in class targeted anti-cancer biologic agent that is positioned to treat a wide range of solid tumors with current clinical trials in rGBM, thyroid cancer and ovarian cancer.
On June 2016 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, VBL reported results from a Phase 1/2 trial of VB-111 in patients with recurrent platinum resistant ovarian cancer. The data demonstrate a median overall survival of 810 days in the VB-111 therapeutic dose arm, versus 172 days in the low dose arm, a result that was statistically significant. There was also a durable doubling in the response rate, as measured by a reduction in the CA-125 biomarker, compared to historical rates of Avastin® (bevacizumab) plus chemotherapy in ovarian cancer. Durable RECIST responses and disease stabilizations were also observed. An immunotherapeutic effect was also observed in biopsies taken from patients. The trial was conducted at Massachusetts General Hospital and Dana Farber Cancer Institute, Boston, MA. under VBL’s IND.
See also the VB-111 Poster at ASCO 2016 .
For more information on the trial please click here.
VBL is planning to launch a Phase 3 pivotal study in platinum-resistant Ovarian Cancer in the second half of 2017.